Lead optimisation
Hit to lead
Assay Development
Therapeutic area
  • Alzheimer’s Disease

Project Aim

To develop a humanised antibody that specifically targets toxic species of Aβ for Alzheimer’s Disease


A novel approach to specifically target Aβ N-terminal oligomers

Target Class

Extracellular Protein



Current Status

Lead with in-vivo proof of concept

Intellectual Property

Existing patent applications with scope for additional IP protection


Licence or collaboration for preclinical / clinical development

Key Contact

  • Hidden
  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
All Licensing Opportunities